Clinical trial
Impact of Magnetic Resonance and Biomarkers for Screening for Prostate Cancer With Different Approaches. Cost-effectiveness Analysis (RMP-BX 2018-01)
NCT04283032 is registered in ClinicalTrials.gov with InvestigatorUrologyIBSAL as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Impact of Magnetic Resonance and Biomarkers for Screening for Prostate Cancer With Different Approaches. Cost-effectiveness Analysis (RMP-BX 2018-01)
- Lead sponsor
- InvestigatorUrologyIBSAL
- Phase
- Observational
- Overall status
- Unknown status
- Start date
- March 1, 2020
- Completion date
- December 31, 2021
- Enrollment
- 628 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
establish if there are differences between transrectal and transperineal prostatic biopsy schemes in both cases with and without mri, establish the association of the tumor biomarker in the early detection and aggressiveness of tumors, establish the efficacy between the four schemes in terms of morbidity associated with the technique, establish the efficacy between the four schemes in terms of the aggressiveness of the tumors according to the gleason classification, establish the efficacy between the four schemes in terms of the patient's subjective perception regarding pain and quality of life, establish the possible interaction between biomarkers and resonance in different prostate biopsy models to define tumor presence and / or tumor aggressiveness, establish the possible relationship between the expression profiles of the micrornas